-
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline
Thursday, July 3, 2014 - 9:39am | 466The hepatitis C industry has been on fire since Merck (NYSE: MRK) paid a 230 percent premium for pharmaceutical company Idenix (NASDAQ: IDIX). Benzinga spoke to Enanta (NASDAQ: ENTA) CEO Jay Luly about possibilities for his firm, which has one of the most expansive hepatitis C pipelines of all...